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REVIEW ARTICLE
Questions and controversies in innate immune research: what
is the physiological role of NLRP3?
RC Coll1, LAJ O’Neill2 and K Schroder1
The NLRP3 inﬂammasome is a key component of the innate immune system that induces pro-inﬂammatory cytokine production
and cell death. Although NLRP3 is activated by many pathogens, it only appears to be critical for host defense for a limited number
of speciﬁc infections. NLRP3 is however strongly associated with the initiation and pathology of many inﬂammatory diseases. If
NLRP3 function is largely redundant for host defense, but drives a number of inﬂammatory diseases, this raises the important
question of why evolution has elected to maintain NLRP3 function. We propose that the primary physiological functions of NLRP3
in health are to engage pathways to clear noxious substances (e.g. protein aggregates and crystals), and to regulate metabolism.
We discuss the newly identiﬁed functions for NLRP3 in metabolic homeostasis, and how NLRP3 beneﬁcial functions in homeostasis
may become detrimental during the onset of inﬂammatory and metabolic diseases. A common feature of most NLRP3-driven
diseases is that they are associated with ageing or metabolic excess, and indeed, Nlrp3 deﬁciency promotes ‘healthspan’ in ageing
mice. This suggests that beneﬁcial functions of NLRP3 in youth may become increasingly countered by NLRP3-dependent
pathology as an individual ages, and we propose a general model by which ageing or nutrient excess may provide a tipping point
to switch NLRP3 function from beneﬁcial to pathological. The physiological role of NLRP3 in healthy individuals remains
incompletely understood and future research will need to address this if NLRP3 is to become a successful therapeutic target for the
clinical management of inﬂammatory diseases.
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FACTS
● Nod-like receptor protein 3 (NLRP3) is a cytosolic pattern
recognition receptor that is activated by a wide range of
pathogen-, host- and environment-derived molecules.
● Active NLRP3 forms a large protein complex called the
inﬂammasome that mediates caspase-1 activation.
● Caspase-1 cleaves the pro-inﬂammatory cytokines interleukin
(IL)-1β and IL-18 to their active secreted forms and also causes a
form of lytic inﬂammatory cell death known as pyroptosis.
● Aberrant NLRP3 activation is associated with many human
inﬂammatory diseases and is an emerging target for drug
development.
OPEN QUESTIONS
● Why is NLRP3 associated with so many inﬂammatory diseases
and how did this situation evolve?
● Is NLRP3 function critical for host defense?
● Does NLRP3 maintain metabolic homeostasis in healthy
individuals?
● What are the IL-1-independent functions of NLRP3?
● Can NLRP3 be safely targeted for inﬂammatory disease
treatment?
In 2001, nod-like receptor protein 3 (NLRP3) mutation was
discovered to cause a group of rare inherited diseases character-
ized by recurrent episodes of inﬂammation.1 Since then, we have
learned that NLRP3 initiates pro-inﬂammatory signaling through
the formation of a protein complex called the inﬂammasome, and
disease-driving mutations potentiate this pathway.2 Activation of
NLRP3 triggers its oligomerisation, which in turn allows for the
recruitment and clustering of the ASC inﬂammasome adapter and
the zymogen protease, caspase-1. Caspase-1 is then activated, and
cleaves the interleukins (ILs)-1β and -18 to generate their active,
secreted forms. Caspase-1 also initiates a form of cell death called
pyroptosis. The NLRP3 inﬂammasome signaling pathway is
illustrated in Figure 1. A number of other NLRs and pattern
recognition receptors (PRRs) can also form inﬂammasomes, the
best studied of these being NLRP1, NLRC4 and AIM2.2 Although
most PRRs are activated by direct interaction with well-deﬁned
ligands, NLRP3 appears to be unique in both the number and
diversity of substances that it can sense. These include microbial,
environmental and host-derived factors such as crystals, protein
aggregates, pore-forming toxins, nucleic acids and ATP. NLRP3 can
thus be regarded as a broad sensor of ‘danger’ or the disruption of
cellular homeostasis, although the precise mechanism(s) by which
NLRP3 senses homeostatic disturbance remain obscure.3
Although NLRP3 is activated by a wide variety of pathogens
including bacteria, viruses, protozoa and fungi, it does not appear
to be critical for host defense for many infections in vivo.4,5 This
may be due to redundancy with other inﬂammasomes, as a
number of pathogens can induce caspase-1 activation and IL-1β
release through multiple inﬂammasome sensors. For example,
both NLRP3 and AIM2 provide resistance in Aspergillus infection,6
and NLRP3 and NLRP1 are both required for survival during
Toxoplasma gondii infection.7 For Gram-negative bacteria,
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deﬁciency in either Nlrp3 or Nlrc4 renders mice more susceptible
to Burkholderia pseudomallei, and NLRP3, NLRC4 and caspase-11
together provide host defense against Salmonella typhimurium.8,9
Redundancy between inﬂammasomes may have evolved to
combat microbial subversion of these sensors.10
Although NLRP3 function appears somewhat redundant during
infection, compelling evidence supports a non-redundant, patho-
logical role of NLRP3 in a large number of inﬂammatory diseases
including metabolic syndrome and type 2 diabetes, non-alcoholic
fatty liver disease/non-alcoholic steatohepatitis, gout, athero-
sclerosis, multiple sclerosis, Alzheimer’s disease and Parkinson’s
disease.11 Nlrp3-deﬁcient mice housed under standard conditions
are generally healthy.12 If NLRP3 is not essential for health, and
indeed may be detrimental, this raises the question of what
physiological function NLRP3 fulﬁlls in healthy individuals. The
established role of NLRP3 as an inﬂammation initiator during
homeostatic disturbance suggests that the physiological role of
NLRP3 may be to restore homeostasis during day-to-day
ﬂuctuations in the cellular environment.13 The clear contribution
of NLRP3 to many inﬂammatory diseases implies that such a
proposed role for NLRP3 only operates within strict boundaries
that are surpassed during disease onset. In this scenario, large or
chronic homeostatic ﬂuctuations would switch the NLRP3 path-
way from beneﬁcial to pathological. Such a pathological role may
avoid the negative selection of Nlrp3 during evolution, since most
NLRP3-driven pathologies are associated with ageing and so may
not compromise reproductive success. NLRP3 may in fact only be
pathologic when the concentration of the offending substance
reaches a certain threshold, the build up (e.g. for factors such as β-
amyloid and cholesterol crystals) being age-related. Otherwise
NLRP3 can promote clearance of the insult without being
detrimental, as might apply during reproductive years. Here we
brieﬂy discuss possible beneﬁcial functions for NLRP3 in
maintaining health, and how these functions may be become
pathological in disease.
NLRP3 IN IMMUNOMETABOLISM
NLRP3 is activated by numerous substances indicative of
metabolic surplus, such as saturated fatty acids,14 ceramides,15
monosodium urate16 and cholesterol crystals.17 NLRP3 is impor-
tant for driving localized inﬂammation in response to noxious
substances such as protein aggregates (e.g. islet amyloid
polypeptide)18 and crystals (e.g. monosodium urate crystals).
NLRP3-dependent IL-1β potently recruits phagocytes that can
digest and remove these harmful particles.16 Thus, NLRP3-
dependent pathways may assist in the removal of noxious
substances.
NLRP3 may also be required for regulating energy metabolism
(extensively reviewed in ref. 13), but here the role of NLRP3 is
more difﬁcult to decipher as it can inﬂuence pro-inﬂammatory
cytokine production (e.g. IL-1β) and cleavage of other caspase-1
substrates in multiple cell types (e.g. hematopoetic and non-
hematopoetic) and tissues (e.g. pancreas and adipose). IL-1β
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Figure 1. The NLRP3 inﬂammasome signaling pathway. NLRP3 inﬂammasome activation requires an initial ‘signal 1’, such as toll-like receptor
or TNF receptor activation, that activates NF-κB. This priming signal induces the transcription of NLRP3 and pro-IL-1β and also results in post-
translational modiﬁcation of the NLRP3 protein, which is required for activation. A second NLRP3-speciﬁc activation signal (‘signal 2’, such as the
metabolic substances indicated) triggers conformational changes resulting in the oligomerization of NLRP3. The adapter molecule ASC is
recruited through Pyrin domain interactions with NLRP3 and forms large prion-like oligomers. The ASC CARD domain interacts with caspase-1
and ASC oligomers provide a scaffold for caspase-1 dimerization, autocatalytic processing and the generation of active caspase-1. Active
caspase-1 processes pro-IL-1β and pro-IL-18 to their active mature forms, which are secreted. Caspase-1 also cleaves Gasdermin-D resulting in
inﬂammatory cell death (pyroptosis).
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signaling has both local and systemic effects that contribute to
regulating energy homeostasis.19 For example, low levels of IL-1β
in the pancreas can induce β-cell proliferation20 and insulin
release,20,21 and so contribute to the restoration of normoglyce-
mia. Early studies with systemically administered IL-1 demon-
strated that it induced anorexia.22 Fatty acids trigger NLRP3
responses,14 NLRP3 regulates triglyceride metabolism via an IL-1β-
independent mechanism,23 and indeed, Nlrp3-deﬁcient mice show
accelerated clearance of triglycerides after a fat challenge.23
Interestingly, NLRP3 functions in steady-state lipid metabolism
were mediated by non-hematopoetic cells.23 In all, these studies
suggest that NLRP3 regulates glucose and triglyceride metabolism
during the normal metabolic ﬂuctuations that occur each day with
nutrient intake and energy expenditure in healthy individuals.
Surprisingly, however, mice deﬁcient in Nlrp3, Asc or Il1r1 fed a
normal chow diet do not show any gross changes in adiposity
compared with wild-type mice.12 This is in contrast to Il18- and
Il18r-deﬁcient mice that are hyperphagic, and become sponta-
neously obese and insulin resistant.24 In this context, the
predominant inﬂammasome controlling IL-18 appears to be
NLRP1, as Nlrp1-deﬁcient mice also become spontaneously
obese.25 This suggests that while NLRP3 activation can trigger
IL-18 secretion, NLRP3-regulated IL-18 is largely dispensable for
metabolic homeostasis in health.
In addition to nutrient surplus, the initiation of metabolic
disease is also associated with mitochondrial dysfunction.26 NLRP3
is a proposed sensor for mitochondrial damage and dysfunction
through direct interaction with mitochondrial DNA and cardioli-
pin, or indirectly, through sensing reactive oxygen species
generated by dysfunctional mitochondria.11 In keeping with a
disease-driving role for NLRP3 activated by nutrient excess and
mitochondrial dysfunction, Nlrp3-deﬁcient mice appear to be
resistant to several metabolic diseases. For example, in murine
high-fat diet models, deﬁciency in Nlrp3, Casp1/11, Asc, Il1b or Il1r
protects mice from developing obesity and insulin
resistance.14,15,27,28 Mechanistically, increased levels of IL-1β
inhibits insulin signaling in adipocytes and hepatocytes, and
induces pancreatic β-cell dysfunction.13 So while NLRP3 and IL-1β
may perform beneﬁcial functions in metabolic regulation in the
steady-state, NLRP3 appears to respond aberrantly to excess, in
this case excessive nutrients and/or dysfunctional mitochondria.
Overall these data suggest that in healthy individuals NLRP3
may be required for sensing metabolic disturbance and initiating
mechanisms that return the system to homeostasis. However, in
the case of chronic exposure to metabolic surplus, the homeo-
static threshold of NLRP3 may be surpassed, resulting in excessive
and detrimental inﬂammation, and ultimately disease. Metabolic
diseases such as type 2 diabetes are generally lifestyle-associated,
and develop in middle to old age, and as such have little impact
on reproductive ﬁtness. NLRP3 may thus be an example of
antagonistic pleiotropy where this gene controls traits that are
both beneﬁcial and detrimental to the organism.29
OTHER POTENTIAL NLRP3 HOMEOSTATIC FUNCTIONS
IL-1 causes a large number of local and systemic biological effects
that have been well characterized over decades.19 As NLRP3
characterization is still ongoing, evidence speciﬁcally linking
NLRP3 to many of these IL-1-mediated processes is still lacking
in many cases. For example, IL-1 is a well-established driver of
hematopoesis in response to infection or myelosupression,19 but
potential roles for NLRP3 in steady-state or emergency hematopo-
esis have not yet been explored in detail. A number of recent
studies have identiﬁed IL-1β-independent functions for NLRP3,
which is not unexpected as caspase-1 cleaves cellular substrates
other than IL-1β and IL-18.30 A number of such examples are
discussed below:
Aging
One of the most intriguing phenotypes observed in aged
(i.e. 418 months) Nlrp3-deﬁcient mice is their prolonged healthspan.12
The age-related decline in glucose tolerance, bone density and
thymic mass observed in mice appears to require NLRP3 but
not IL-1 signaling, while the NLRP3/IL-1 axis was required for
age-related cognitive decline associated with central nervous
system inﬂammation.12
Microbiome
A single study comparing naïve wild type and Nlrp3− /− littermates
found there were 10 bacterial genera clearly enriched in the fecal
microbiota of Nlrp3-deﬁcient animals.31 Currently, the function of
NLRP3 in the intestine remains controversial with reports of both
protective and deleterious effects of NLRP3, particularly in murine
models of colitis.32 Additional carefully controlled studies to
examine NLRP3 pathways in intestinal homeostasis are clearly
required.
Transcription
A recent article by Bruchard et al.33 demonstrated that
NLRP3 binds to the IL-4 promoter in CD4+ T cells. In this context,
NLRP3 functioned independently of inﬂammasomes as a tran-
scriptional regulator to inﬂuence Th2 cell differentiation.33 Thus,
inﬂammasome-independent NLRP3 may inﬂuence adaptive
immunity and Th2 responses.
A summary of the current knowledge of the homeostatic
functions of NLRP3 is shown in Figure 2.
CONSIDERATIONS FOR NLRP3 TARGETING IN DISEASE
We recently characterized an NLRP3 small molecule inhibitor
called MCC950.34 Our data suggests that NLRP3 inhibition by a
small molecule may offer a new, more-targeted approach for
treating NLRP3-driven diseases than current biologics that block
IL-1 signaling. Given the above discussion of possible beneﬁcial,
homeostatic NLRP3 functions, the potential detrimental effects of
NLRP3 inhibition should also be considered. For example, could
such therapy increase a patient’s risk of infection? IL-1 blockade in
patients does cause a small increase in the incidence of
infections.35 However, the redundancy within and between IL-1-
producing inﬂammasomes and other PRR pathways suggests
NLRP3 inhibition will likely not generally predispose to infection,
although it could increase risk to a small number of speciﬁc
infections for which NLRP3 plays a non-redundant role in
pathogen control, such as Candida albicans.36 It is also possible
that blocking all pathways downstream of NLRP3 (i.e. IL-1, IL-18
and pyroptosis) could provide a beneﬁcial niche for a pathogen
sensed by this pathway.
NLRP3
Triglyceride metabolism
β cell proliferation
Pathogen clearance
Th2 cell differentation
Microbiome homeostasis
Insulin release
Recruitment of phagocytes
Decreased healthspan
Figure 2. Positive regulatory functions for NLRP3 in homeostasis.
NLRP3 has a number of functions in metabolism such as regulating
insulin release, β-cell proliferation and triglyceride levels. New IL-1β-
independent functions of NLRP3 have been identiﬁed in regulating
ageing, intestinal microbiota and during transcription in Th2 cells.
NLRP3 is required for the sensing of pathogens such as Candida and
in the recruitment of phagocytes to clear infections and noxious
protein aggregates and crystals.
What is the physiological role of NLRP3?
RC Coll et al
3
© 2016 Cell Death Differentiation Association Cell Death Discovery (2016) 16019
A number of studies have investigated NLRP3 in cancer, with
reports of both anti-carcinogenic and pro-tumorigenic roles for
NLRP3.37 For example, in a recent report, murine Nlrp3 deﬁciency
increased metastatic foci in the liver in a model of colorectal
cancer metastasis.38 Another report linked NLRP3 expression and
caspase-1 activation to glucocorticoid resistance in leukemia
cells,39 suggesting that blocking NLRP3 and caspase-1 activation
in the latter context would be beneﬁcial. Clearly the function of
NLRP3 needs further research, especially when considering the
potential long-term use of an NLRP3 inhibitor in patients with
chronic diseases, but such an approach represents a new and
exciting way to treat inﬂammation-driven diseases.
As NLRP3 activation is associated with many metabolic diseases
that only develop later in life, NLRP3 blockade in older individuals
may present more health beneﬁts than risks. Given the evidence
that long-term inﬂammation is linked with age-related decline in
health40 and that NLRP3 may be a driving force in this process,12 it
is tempting to speculate that NLRP3 inhibition could be a useful
clinical strategy for prolonging healthspan.
FUTURE RESEARCH
Although huge advances have been made in our understanding
of the role of NLRP3 in health and disease, the basic mechanism of
NLRP3 activation is still incompletely characterized.3 On a
molecular level, understanding the NLRP3 inﬂammasome has
been hampered by a lack of protein structural information. The
structures of ASC and caspase-1 are available, but for NLRP3, the
Pyrin domain is the only domain to have been solved.41 Structure
solution for full-length NLRP3 would provide valuable insight into
its mechanism of auto-inhibition, oligomerization and interaction
with ASC. Accurate modeling of the entire inﬂammasome complex
would also aid the design of NLRP3 inhibitors.
There is currently a paucity of data on the function of NLRP3 in
homeostasis in healthy animals, as until now, the ﬁeld’s focus has
been the pathological roles of NLRP3 in disease. It will be
important to further explore how NLRP3 maintains homeostasis in
health, for example, the mechanisms by which NLRP3 maintains
gut microbiota and regulates triglyceride metabolism, to under-
stand the possible risks of NLRP3 inhibitory therapy in human
patients. It will also be of great interest to determine whether
NLRP3 blockade in human disease can reproduce the protection
offered by Nlrp3 deﬁciency in murine models of disease.
CONCLUSION: A MODEL FOR THE PHYSIOLOGICAL ROLE
OF NLRP3
In summary, we propose the following model for NLRP3 function
in homeostasis and disease. We suggest that a primary role of
NLRP3 at any age is to sense noxious stimuli that accumulate, with
NLRP3 driving inﬂammation to facilitate their clearance (Figure 3).
These factors might accumulate in the course of normal tissue
damage, and the NLRP3 response would be self-limiting as the
clearance succeeds. However, with age (or indeed earlier in life if
there is nutrient excess), NLRP3 becomes pathologic either
because of too strong a response or because of the over-
activation of macrophages due to the chronic presence of
excessive amounts of substances such as β-amyloid or MSU
crystals. Another primary function of NLRP3 may be in infection,
but this has evolved to be largely redundant with other
inﬂammasomes or inﬂammasome-independent mechanisms of
IL-1 production,42 likely due to the selection pressure exerted by
pathogens attempting to subvert NLRP3. NLRP3 may therefore
prove to be an ideal therapeutic target for major pathologies that
continue to afﬂict humanity. As with social interactions between
humans, the ageing process might give rise to irritation, NLRP3 in
Any age Older age
Infection Inflammatory stimuli
(sub-pathologic)
Inflammatory stimuli
(in excess)
eg. MSU crystals, IAPP, β-amyloid
Nutrient excess
Disease
NLRP3
Other 
Inflammasomes
NLRP3NLRP3
Restoration of 
homeostasis
Unable to restore homeostasis
Detrimental inflammationBeneficial inflammation
Chronic     activation
Figure 3. Model of the physiological role of NLRP3. NLRP3 function may be largely redundant during infection, with other inﬂammasomes also
able to provide defense. NLRP3-dependent inﬂammation contributes to the restoration of homeostasis when the provoking stimuli (e.g.
products of damaged tissue, including crystals) are present at low levels. In cases of excess (e.g. in response to nutrients in a high-fat diet, or
high levels of deposition of noxious stimuli such as MSU crystals, or protein aggregates such as β-amyloid or IAPP), however, NLRP3 drives
chronic inﬂammation, which is pathological. These events are more likely to occur with ageing, which is associated with the accumulation of
such substances. Such a pathological function for NLRP3 would likely not be inﬂuenced by negative selection during evolution, as
reproductive success would not be sufﬁciently affected. The issue in essence may therefore be one of dose—NLRP3 sensing low dose in youth
being beneﬁcial, high dose in age being detrimental.
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effect becoming the ‘grumpy old man’ of inﬂammation, irritated
by excesses and driving diseases that are ultimately self-defeating.
Reining in this behavior might, therefore, bring substantial
beneﬁts to all concerned.
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